Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
39 Results for "
Mycobacteria tuberculosis
" in MedChemExpress (MCE) Product Catalog:
Products (39)
39 Results for "Mycobacteria tuberculosis" in MCE Product Catalog:
4
4 Cited Publications
Synonyms: PNU-100480; U-100480; PF-02341272
Target:
Research Areas:
Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis .
4
4 Cited Publications
BM212 is a potent Mycobacterial membrane protein Large 3 (MmpL3) inhibitor. BM212 has strong bactericidal activity against both M. tuberculosis and some nontuberculosis mycobacteria. BM212 exhibits antimycobacterial activity against M. tuberculosis H37Rv with an MIC of 5 µM .
4
Target:
Research Areas:
SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) .
1
1 Cited Publications
Cat. No.: HY-N1976
CAS No.: 225110-25-8
Synonyms: (3R,8S)-Falcarindiol; 3(R),8(S),9(Z)-Falcarindiol
Cat. No.: HY-D2919
CAS No.: 2177287-88-4
Synonyms: PNU-100592
Target:
Research Areas:
Eperezolid (PNU-100592) is an orally active protein synthesis inhibitor that targets the bacterial 50S ribosomal subunit. Eperezolid competitively binds to a specific site on the ribosomal 50S subunit (overlapping with the binding sites of chloramphenicol (HY-B0239) and lincomycin (HY-117660)) to inhibit the translation initiation stage and exert antibacterial activity. Eperezolid can induce host cell autophagy to enhance the clearance of intracellular mycobacteria, and its MIC90 for Staphylococcus aureus and Enterococcus is 1-4 μg/mL. Eperezolid is mainly used for antibacterial research on infections with Gram-positive bacteria such as methicillin-resistant (HY-121544) Staphylococci and vancomycin-resistant (HY-B0671) Enterococci, as well as infections with intracellular bacteria such as Mycobacterium tuberculosis .
Cat. No.: HY-P4284
CAS No.: 35172-59-9
Target:
Research Areas:
Synonyms: KRM-1648; ABI-1648
Target:
Research Areas:
Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase . Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml . Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB) .
Cat. No.: HY-145301
CAS No.: 65840-95-1
Mycobactin-IN-1, a pyrazoline analogue, is a mycobactin biosynthesis inhibitor against mycobacteria. Mycobactin-IN-1 binds to salicyl-AMP ligase (MbtA), a key enzyme in the mycobactin biosynthetic pathway. Mycobactin-IN-1 inhibits whole-cell drug efflux pumps in M. smegmatis. Mycobactin-IN-1 eradicates intracellularly surviving mycobacteria. Mycobactin-IN-1 shows an excellent in vivo pharmacokinetic profile. Mycobactin-IN-1 can be used for the research of tuberculosis .
Research Areas:
Thiolactomycin is an orally active bacterial type II fatty acid synthase (FAS-II) inhibitor with antibacterial and antimalarial activities. Thiolactomycin specifically targets KasA/KasB in mycobacteria and FabB/FabF in bacteria, thereby inhibiting the biosynthesis of fatty acids and mycolic acids. Thiolactomycin can be used in studies related to tuberculosis, systemic bacterial infections, and experimental pyelonephritis .
Synonyms: (R)-GSK1729177A
Target:
Research Areas:
MMV688845 is a nontuberculous mycobacteria (NTM) RNA polymerase inhibitor with bactericidal activity against Mycobacterium abscessus and anti-tuberculosis efficacy .
Target:
Research Areas:
Protein serine/threonine kinase (Ser/Thr protein kinase) is a signal transduction molecule. Protein serine/threonine kinase phosphorylates specific residues on target substrates, regulates phosphorylation-dependent signal cascades, modulates cellular processes of mycobacteria, blocks phagosome-lysosome fusion, promotes meiotic maturation of Xenopus laevis (African clawed frog) oocytes, rescues the phenotype of Saccharomyces cerevisiae (budding yeast) CDC5 mutants, and exhibits cell cycle phase-specific kinase activity. Protein serine/threonine kinase maintains a tightly regulated cell cycle expression pattern, and sustains the growth and survival of mycobacteria. Protein serine/threonine kinase can be used in studies related to tuberculosis .
Cat. No.: HY-N10069
CAS No.: 83162-84-9
Target:
Cat. No.: HY-W026339
CAS No.: 921812-26-2
IMB-XMA0038 is a MtASADH inhibitor with an IC50 value of 0.59 μg/mL. IMB-XMA0038 inhibits various agent-resistant Mycobacteria tuberculosis potently with MICs of 0.25-0.5 μg/mL. IMB-XMA0038 shows anti-tuberculosis activity .
Cat. No.: HY-10392R
CAS No.: 168828-58-8
Synonyms: PNU-100480 (Standard); U-100480 (Standard); PF-02341272 (Standard)
Target:
Research Areas:
Sutezolid (Standard) is the analytical standard of Sutezolid. This product is intended for research and analytical applications. Sutezolid (PNU-100480), an orally active oxazolidinone antimicrobial agent, acts by inhibiting bacterial protein synthesis. Sutezolid has potent activity against mycobacteria, and is used for the research of drug-resistant tuberculosis[1][2].
Cat. No.: HY-146702
CAS No.: 2990619-92-4
Target:
Research Areas:
MtTMPK-IN-8 (compound 27) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor. MtTMPK-IN-8 has sub-micromolar activity against mycobacteria (MICs = 0.78~9.4 μM) without significant cytotoxicity. MtTMPK-IN-8 can be used for researching tuberculosis .
Cat. No.: HY-146701
CAS No.: 2987482-25-5
Target:
Research Areas:
MtTMPK-IN-7 (compound 26) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 47 μM. MtTMPK-IN-7 has sub-micromolar activity against mycobacteria (MICs = 2.3~4.7 μM) without significant cytotoxicity. MtTMPK-IN-7 can be used for researching tuberculosis .
Cat. No.: HY-146703
CAS No.: 2987299-68-1
Target:
Research Areas:
MtTMPK-IN-9 (compound 28) is a moderate M. tuberculosis thymidylate kinase (MtbTMPK) inhibitor with an IC50 value of 48 μM. MtTMPK-IN-9 has sub-micromolar activity against mycobacteria (MICs = 6.25~9.4 μM) without significant cytotoxicity. MtTMPK-IN-9 can be used for researching tuberculosis .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
